Pharmaceutical composition comprising a gamma-cyclodextrin-based polymer

today’s cyclodextrin:
it makes me particularly happy to post about the recent success of Heegon Kim and RENATUS, as I have known and admired Heegon’s work for a while and we share a vision of the importance of developing CD-based therapies. Renatus develops gamma-cyclodextrin-based polymer to prevent or treat cholesterol metabolism-related diseases to minimize cell membrane cholesterol extraction, thus exhibiting an excellent anti-inflammatory effect by causing no cytotoxicity and hemolytic activity, making intracellular cholesterol metabolism and release easy and effectively inhibiting the release of IL-1β, MCP-1, and TNF-α.

See the complete patent here: PHARMACEUTICAL COMPOSITION COMPRISING GAMMA-CYCLODEXTRIN POLYMER AND USE THEREOF


Targeting bacterial virulence as a novel treatment against AMR infections

Have you known that Arivin Therapeutics uses cyclodextrin for targeting bacterial virulence as a novel treatment against AMR infections? Among their MoA claims, the following are listed:
– Targeting virulence factors is effective, also against extensively resistant isolates
– Targeting virulence avoids rapid resistance
– Direct reduction in inflammatory responses
– Potentiates the function of antibiotics
Also, there is a spectacular video about how CDs develop their effect as antibacterials.

https://arivintx.com/our-science